HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences

被引：0

作者：

Mikasi, Sello Given ^{[1
]}

Isaacs, Darren ^{[2
]}

Ikomey, George Mondinde ^{[3
]}

Shimba, Henerico ^{[1
,4
]}

Cloete, Ruben ^{[3
]}

Jacobs, Graeme Brendon ^{[1
]}

机构：

[1] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Pathol, Div Med Virol, ZA-7505 Cape Town, South Africa

[2] Univ Western Cape, South African Natl Bioinformat Inst, South African Med Res Council, Bioinformat Unit, Cape Town, South Africa

[3] Univ Yaounde I, Fac Med & Biomed Sci, Ctr Study & Control Communicable Dis, Yaounde, Cameroon

[4] Bugando Med Ctr, Mwanza, Tanzania

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2021年 / 37卷 / 01期

基金：

新加坡国家研究基金会; 英国医学研究理事会;

关键词：

HIV-1; integrase; resistance; Cameroon; diversity; CRF02_AG; DOLUTEGRAVIR; RALTEGRAVIR;

D O I：

10.1089/aid.2020.0022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

HIV-1 integrase (IN) is a primary target for combination antiretroviral therapy. Only a limited number of studies report on the emergence of resistance-associated mutations (RAMs) in Cameroon. We observed that 1.4% of sequence from treatment-naive patients had IN strand transfer inhibitor (INSTI) RAMs. These mutations confer resistance to raltegravir and elvitegravir. We also observed that 10.1% of the sequences have INSTI accessory RAMs. HIV-1 CRF02_AG was the predominant subtype (44.7%) in this study analyses. The occurrence of INSTI RAMs among the sequences at baseline needs to be monitored carefully.

引用

页码：54 / 56

页数：3

共 50 条

[21] HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes
Reigadas, S.
Marcelin, A. G.
Houssaini, A.
Yerly, S.
Descamps, D.
Plantier, J. C.
Ruffault, A.
Amiel, C.
Trabaud, M. A.
Flandre, Philippe
Fleury, H.
Masquelier, B.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (04) : 969 - 972
[22] Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
Tzou, Philip L.
Rhee, Soo-Yon
Descamps, Diane
Clutter, Dana S.
Hare, Bradley
Mor, Orna
Grude, Maxime
Parkin, Neil
Jordan, Michael R.
Bertagnolio, Silvia
Schapiro, Jonathan M.
Harrigan, P. Richard
Geretti, Anna Maria
Marcelin, Anne-Genevieve
Shafer, Robert W.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (01) : 170 - 182
[23] Drug resistance in HIV-1
Kuritzkes, Daniel R.
CURRENT OPINION IN VIROLOGY, 2011, 1 (06) : 582 - 589
[24] Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes
Jain, Vivek
Sucupira, Maria C.
Bacchetti, Peter
Hartogensis, Wendy
Diaz, Ricardo S.
Kallas, Esper G.
Janini, Luiz M.
Liegler, Teri
Pilcher, Christopher D.
Grant, Robert M.
Cortes, Rodrigo
Deeks, Steven G.
Hecht, Frederick M.
JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (08): : 1174 - 1181
[25] DYNAMICS BEHAVIOR OF MUTATION DURING REPRODUCTION ON HIV-1 DRUG RESISTANCE
Huang, Guangyu
Fan, Aijun
Wang, Kaifa
INTERNATIONAL JOURNAL OF BIOMATHEMATICS, 2013, 6 (03)
[26] Peptides derived from HIV-1 Rev inhibit HIV-1 Integrase in a shiftide mechanism
Hayouka, Zvi
Rosenbluh, Joseph
Levin, Aviad
Maes, Michal
Loyter, Abraham
Friedler, Assaf
BIOPOLYMERS, 2008, 90 (04) : 481 - 487
[27] The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
Malet, Isabelle
Fourati, Slim
Charpentier, Charlotte
Morand-Joubert, Laurence
Armenia, Daniele
Wirden, Marc
Sayon, Sophie
Van Houtte, Margriet
Ceccherini-Silberstein, Francesca
Brun-Vezinet, Francoise
Perno, Carlo-Federico
Descamps, Diane
Capt, Andre
Calvez, Vincent
Marcelin, Anne-Genevieve
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (12) : 2827 - 2830
[28] Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa
Brado, Dominik
Obasa, Adetayo Emmanuel
Ikomey, George Mondinde
Cloete, Ruben
Singh, Kamalendra
Engelbrecht, Susan
Neogi, Ujjwal
Jacobs, Graeme Brendon
SCIENTIFIC REPORTS, 2018, 8
[29] Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa
Dominik Brado
Adetayo Emmanuel Obasa
George Mondinde Ikomey
Ruben Cloete
Kamalendra Singh
Susan Engelbrecht
Ujjwal Neogi
Graeme Brendon Jacobs
Scientific Reports, 8
[30] Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
Siedner, Mark J.
Moorhouse, Michelle A.
Simmons, Bryony
de Oliveira, Tulio
Lessells, Richard
Giandhari, Jennifer
Kemp, Stephen A.
Chimukangara, Benjamin
Akpomiemie, Godspower
Serenata, Celicia M.
Venter, Willem D. F.
Hill, Andrew
Gupta, Ravindra K.
NATURE COMMUNICATIONS, 2020, 11 (01)

← 1 2 3 4 5 →